Expert Interviews

Centering discussion on RedirecTT-1, expert hematologist-oncologists consider safety and efficacy data with the combination of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.

Shared perspective on available novel therapies in relapsed/refractory multiple myeloma and how best to sequence these agents.

The expert panel review recently reported data from clinical trials evaluating menin inhibitors, including ziftomenib and revumenib, in the treatment of relapsed AML and how these treatments may fit into first-line settings.

Daniel Pollyea, MD, MS, discusses first-line treatment options for patients with AML with KMT2a rearrangements.

Closing thoughts on unmet needs in the multiple myeloma space, particularly disparities in the care of patients with MM of racial and ethnic minorities.

Dr. Cook and Dr. Pianko share their perspectives on optimizing treatment strategies for individual patients in order to maximize response and mitigate adverse events.

Moshe Ornstein, MD, explains how he selects a frontline IO/TKI combination regimen for a patient with advanced renal cell carcinoma.

Dr Brian Rini shares his view on the data comparing IO/TKI and IO/IO combination regimens for the treatment of advanced renal cell carcinoma.

A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.

Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.

Defining transplant eligibility, explaining the role of transplant in NDMM, and differentiating between high- and low-risk MM.

Thoughtful discussion centered around recently presented updates to the GRIFFIN, MASTER, and GMMG-CONCEPT studies in NDMM patients.

Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.

Centering focus on the first-line treatment armamentarium, key opinion leaders consider factors that aid in the selection of best therapy for patients with advanced bladder cancer.

A brief discussion on supportive care available to patients with bladder cancer and the role it plays within the treatment pathway.

Key opinion leaders consider when it is appropriate to utilize bispecific dose holds or reductions when treating patients with multiple myeloma.

Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.

The panel highlights remaining unmet needs in the management of multiple myeloma and speculates on the future of treatment.

Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.

Expert perspectives on clinical trial data and personal experience with amivantamab in the setting of EGFR Exon20+ non–small cell lung cancer.